Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    


Fighting Alzheimer's Head-on


 

Vanderbilt Research Could Redefine Alzheimer's Treatment

More than five million Americans are living with Alzheimer's disease, a diagnosis that kills more people yearly than breast and prostate cancers combined. Fortunately there's hope on the horizon, thanks to a number of studies and trials underway at Vanderbilt University Medical Center.

A potential new drug for Alzheimer's and schizophrenia developed by Vanderbilt University scientists was recently administered to the first volunteer at Vanderbilt Institute for Clinical and Translational Research. Animal studies suggest that the compound, a small molecule called VU319, may have potential for reducing memory impairments in brain disorders.


A Long Time Coming


Paul Newhouse, MD

"There's been an effort at Vanderbilt to develop new molecules for neuropsychiatric illnesses for several years," said Paul Newhouse, MD, director of the Vanderbilt Center for Cognitive Medicine.

The molecule was discovered several years ago at the Vanderbilt Center for Neuroscience Drug Discovery through a team of scientists led by center director Jeffrey Conn, PhD, and co-director Craig W. Lindsley, PhD.

"We realized this would be of particular interest for patients with Alzheimer's and began collaboration with Drs. Conn and Lindsley to try to move this drug from discovery into human trials," Newhouse said. "It's one thing to discover a new molecule and test it in rats, but it's another to get approval to put a new drug into humans."

The molecule received FDA approval for human trials November 2016 and began the first-in-human Phase 1 clinical trial in July. "This is a novel achievement because we're the first university to go from molecular discovery to testing in humans in the same university for a new potential Alzheimer's disease treatment," said Newhouse. Once a molecule is discovered, he explained, schools typically license it to a commercial entity to help defray development costs.

Trial Opportunities

Enrollment is still open for the randomized double-blind, placebo-controlled study, which will be conducted in approximately 100 healthy adult volunteers over the next year. The single dose cohort, which concludes next spring, will help determine the compound's safety, tolerability and bioavailability when taken orally. Dosage will gradually be increased in participants until it reaches the highest level of exposure previously administered in animals.

Trial participants undergo testing for brain effects using sophisticated computerized cognitive testing and EEG. While the molecule isn't a cure for Alzheimer's, it's expected to enhance attention, memory and learning earlier than ever.

"We've known for years that a certain chemical system is deficient in patients with Alzheimer's so medications typically try to enhance that indirectly," said Newhouse. The new molecule attempts to directly stimulate that system in a way that's never been done and could be used independently or as a complimentary therapy. Newhouse also believes it could be administered at the onset of symptoms to help slow progression of the disease.

Alzheimer's Treatment Past & Present

Historically, innovation in Alzheimer's therapies has been remarkably slow, with a failure rate of over 99 percent. In fact, the last FDA approved Alzheimer's drug was introduced some 15 years ago.

"There's still a lot we don't know about Alzheimer's, and that's disconcerting to us," said Newhouse. "We thought we understood the biology, but it's more complex than we thought."

That's because the predominant theory of what's causing the illness might be true ... but changing those proteins doesn't necessarily alter symptoms. Still, researchers are hopeful about the molecule's cognitive benefits due to promising evidence from preclinical studies.

VU319 isn't the only potential game-changer coming out of Vanderbilt. "We're doing a lot here in terms of clinical trials in Alzheimer's patients with new therapies, including collaborating with pharmaceutical companies," he said. "We're focused on early stage, as well as prevention."

Newhouse also is the national lead investigator for a 27-site study through the National Institute on Aging. The Memory Improvement Through Nicotine Dosing study uses transdermal nicotine patches to enhance early memory loss. The MIND study is a collaboration between Vanderbilt and the University of Southern California's Alzheimer's Therapeutic Research Institute.

Another NIA study, the Alzheimer's Disease Neuroimaging Initiative, looks at history, biomarkers and symptoms to better distinguish between dementia and Alzheimer's. Participants receive specialized scans and spinal fluid analysis not available to the general public.

"Not every dementia is Alzheimer's, and it's important for any family to make sure they get an accurate diagnosis," Newhouse said. "Seniors are living longer, and brain health is becoming ever more critical. The sad reality is that the percentage of patients diagnosed is increasing, although it's better recognized than it used to be."


Protecting the Brain

Newhouse also wants to dispel common myths related to aging. "There's a belief that as you get older memory inevitably becomes worse, but that's not true," Newhouse said. "The brain is not immune to age-related changes, but brain function overall should not decline." To that end, lifestyle choices are now recognized as an increasingly important aspect of protecting brain function during aging.

"There's no question that paying attention to lifestyle will make a significant dent in dementia outcomes," Newhouse said. "We can't prevent it, but we know we can do a lot to reduce risk; and we're beginning to think about ways we can help younger and middle age people reduce their risk earlier in life. Identifying those at increased risk is something I'm quite passionate about, and it's being seen as a new approach to treating this disease."


WEB:

VUMC

Vanderbilt Center for Cognitive Medicine

Vanderbilt Center for Neuroscience Drug Discovery

 
Share:

Related Articles:


Recent Articles

AMA Supports Congress Providing Much-Needed Relief to Physicians Working Through the Pandemic

CHICAGO -- The American Medical Association (AMA) strongly supports provisions in the Continuing Resolution that will offer relief to hard-pressed physician practices. Revisions to the Medicare Accelerated and Advance Payments program (AAP) will help keep doors open during the pandemic and continue to offer patients access at this time.

Read More

AMA Releases 2021 CPT Code Set

New updates to medicine's common language reflect burden relief, COVID-19 testing and tech-enabled medical services

Read More

Council on Aging Offers Helpline, Resources for Healthcare Providers

COA offers a helpline and lifeline to providers, older adults, caregivers and family members trying to navigate services.

Read More

VUMC Launches Groundwork for Tennessee's First Federally Funded Alzheimer's Disease Research Center

Angela Jefferson, PhD, professor of Neurology and director of the Vanderbilt Memory and Alzheimer's Center, has been awarded a grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to support establishment of an NIA-funded exploratory Alzheimer's Disease Research Center (ADRC) at Vanderbilt University Medical Center (VUMC).

Read More

From Pain Management to Pandemic: The Changing Face of Sports Medicine

New norms mean new routines and standards of care on and off the field.

Read More

Kids, Classrooms and COVID-19

Risk mitigation key as kids hit the classrooms.

Read More

Meharry, Wharton Partner on Dual Degree Program

Meharry Medical College and the Wharton School at the University of Pennsylvania have partnered on a joint MD/PhD program.

Read More

Practice Management Q&A with NMGMA

NMGMA leaders answer questions about challenging practice management issues.

Read More

Physician Practice Leadership in a Post-COVID-19 Environment

COVID-19 has changed just about every aspect of daily life, including the way care is delivered. Looking toward a post-COVID landscape, practice leaders will need to reevaluate processes and assess the best way forward.

Read More

Economic Effect of COVID-19 Shutdowns & PPP Relief

A public health crisis, COVID-19 has also proven to be an economic crisis for practices and providers. For those receiving PPP relief, the path to forgiveness is coming into focus.

Read More

Email Print
 
 

 

 


Tags:
Alzheimer's, Craig W. Lindsley, Dementia, Jeffrey Conn, Paul Newhouse, Schizophrenia, Senior Health, Vanderbilt Center for Cognitive Medicine, Vanderbilt Center for Neuroscience Drug Discovery, VU319
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: